SCHEMBL17248014

SCHEMBL17248014

Cc1cnc(OC(F)F)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
GAA P10253 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
RXRA P19793 5/20 0.33
GRIN1 Q05586 5/20 0.33
GRIN2B Q13224 5/20 0.33
CCR1 P32246 1/20 0.33
CCR5 P51681 1/20 0.33
CCR8 P51685 1/20 0.33
SSTR4 P31391 4/20 0.32
F2RL3 Q96RI0 2/20 0.31
TRPV4 Q9HBA0 1/20 0.31
PIK3CA P42336 1/20 0.31
PSMD14 O00487 1/20 0.31
COPS5 Q92905 1/20 0.31
CYP1A2 P05177 1/20 0.31
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21585391 0.82 AGBL2 (0.39) GAAHCRTR1HCRTR2SSTR4TRPV4
SCHEMBL24174271 0.82 GAA (0.38) NOS3NOS1NOS2GAARXRA
SCHEMBL11962330 0.82 NOS3 (0.43) NOS3NOS1NOS2CCR1CCR5
SCHEMBL15052308 0.81 AAK1 (0.38) GAAHCRTR1HCRTR2RXRAGRIN1
SCHEMBL27042313 0.81 HCRTR1 (0.34) NOS3NOS1NOS2GAAHCRTR1
SCHEMBL16044313 0.81 GAA (0.35) NOS3NOS1NOS2GAARXRA
SCHEMBL15599228 0.81 GAA (0.37) GAAHCRTR1HCRTR2RXRAGRIN1
SCHEMBL17055785 0.79 AGBL2 (0.41) HCRTR1HCRTR2SSTR4CYP1A2KMT2A
SCHEMBL18371940 0.79 LPAR1 (0.37) NOS3NOS1NOS2GAARXRA
SCHEMBL25950819 0.78 ALDH1A1 (0.34) GAARXRAGRIN1GRIN2BSSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020534-A2 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. (US) 2024-01-25 WO disclosed
US-9550775-B2 Substituted triazolopyridines and methods of use thereof GENENTECH, INC. (US) 2017-01-24 US disclosed
US-9493429-B2 Substituted benzoxazoles and methods of use thereof GENENTECH, INC. (US) 2016-11-15 US disclosed
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2016-01-14 US disclosed
US-20160009667-A1 SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-01-14 US disclosed
US-20150322002-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322002-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, SNRPD2, RDX NOS3 1021/4885NOS1 1122/4885NOS2 1019/4885
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF P2RX3, P2RX1, P2RX4 NOS3 920/4885NOS1 1582/4885NOS2 1375/4885
US-20160009667-A1 SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF CYP4X1, BRIX1, HAX1 NOS3 2028/4885NOS1 2792/4885NOS2 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.